Quantcast

Latest Boehringer Ingelheim Stories

2014-06-27 08:25:26

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and INGELHEIM, Germany, June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company and Boehringer Ingelheim is the first biosimilar insulin...

2014-06-27 08:25:19

First biosimilar insulin to receive CHMP positive opinion in the EU INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim is the first...

2014-06-26 08:28:27

Idarucizumab being evaluated to specifically reverse the anticoagulant effect of PRADAXA RIDGEFIELD, Conn., June 26, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to idarucizumab*, an investigational fully humanized antibody fragment, or Fab, being studied as a specific antidote for Pradaxa (dabigatran etexilate mesylate). "Boehringer Ingelheim is pleased that the...

2014-06-24 12:28:44

RIDGEFIELD, Conn., June 24, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the company has initiated an open-label, U.S. multi-center expanded access program (EAP) for its investigational compound nintedanib, for people diagnosed with idiopathic pulmonary fibrosis (IPF) and who meet certain eligibility criteria. Nintedanib is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA). The safety and efficacy of...

2014-06-23 23:03:39

Nation’s Premier Annual Physical Activity and Hispanic Family Health Celebration – Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company presenting Llaves para una mejor salud (Keys to a Healthier You) diabetes education pavilion. Univision and 5 de Mayo sponsor youth soccer tournament. Chicago, IL (PRWEB) June 23, 2014 On Saturday, June 28, 2014, the National Alliance for Hispanic Health with the Chicago Hispanic Health Coalition presents ¡Vive tu vida! Get Up!...

2014-06-19 23:17:50

Boehringer Ingelheim GmbH, a German pharmaceutical company, recently announced a settlement for approximately 4,000 claims related to injuries and deaths caused by the blood thinner Pradaxa. PHOENIX, AZ (PRWEB) June 19, 2014 The Arizona personal injury firm Phillips Law Group is investigating claims against Boehringer Ingelheim GmbH, the pharmaceutical company who makes the blood thinner Pradaxa. On May 28, a Bloomberg report announced that Boehringer had agreed to settle approximately...

2014-06-19 23:17:47

German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States. The Pradaxa blood thinner is alleged to have cause injuries and fatalities. WINSTON-SALEM, NC (PRWEB) June 19, 2014 Mike Lewis Attorneys, a product liability firm in Tennessee, is reviewing and investigating the impact of Boehringer Ingelheim’s $650 million settlement offer. If successful, the offer would settle more than 4,000 pending Pradaxa claims in the United States. In...

2014-06-19 23:17:43

German pharmaceutical company Boehringer Ingelheim GmbH has agreed to settle nearly 4,000 claims against the drug company for injuries and deaths caused by the blood thinner Pradaxa. MCALESTER, OK (PRWEB) June 19, 2014 The Edwards Law Firm, an Oklahoma pharmaceutical litigation firm, continues to investigate and pursue claims regarding Pradaxa, a blood thinner manufactured by Boehringer Ingelheim GmbH. A Bloomberg report on May 28 announced that Boehringer had agreed to pay $650 million...

2014-06-19 08:28:42

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious and well-tolerated as an add-on treatment in Japanese adults with moderate to severe symptomatic asthma, despite treatment with inhaled corticosteroids (ICS) with or without long-acting beta-2 agonist (LABA). "Even with available treatments, the extent to which patients' asthma is controlled...

2014-06-17 16:26:03

-- No additional clinical trials requested by the FDA RIDGEFIELD, Conn. and INDIANAPOLIS, June 17, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA). The Class 1 resubmission...


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.